跳到正文
原文
STAT Pharma 医药频道· Margaret Manto·· 16 天前AI 评分38

Bernie Sanders 或将主导 FDA 资金法案谈判

STAT+: Pharma critic Bernie Sanders is set to hold major sway over FDA funding bill

AI 导读

民主党在中期选举中取得压倒性胜利,可能对即将进行的 FDA 资金法案谈判产生重大影响,其中关键权力将落在反对用户费结构的参议员 Bernie Sanders 手中。FDA 依靠制药公司缴纳的用户费来资助药品审批工作。

正文

WASHINGTON – Democrats’ landslide victory in the midterm elections may have significant implications for the upcoming negotiations over a key funding source for the Food and Drug Administration in part by empowering a major critic of the program.

The FDA collects user fees from pharmaceutical companies to fund the agency’s reviews of their medicines. The Prescription User Fee Drug Act must be renewed before the current law expires on Sept. 30. Otherwise, it could disrupt the FDA’s ability to approve medicines.

The power to shape that legislation will fall to senior Democrats, including Sen. Bernie Sanders (I-VT), who is likely to lead the Senate’s health committee. Sanders is one of the few lawmakers who have opposed the core premise of the user fee structure. 

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT Pharma 医药频道 · statnews.com